[
    {
        "text": "Thank You CNN for this great honor I",
        "start": 0.03,
        "duration": 4.11
    },
    {
        "text": "would also like to thank all the people",
        "start": 2.04,
        "duration": 3.09
    },
    {
        "text": "who are involved in the selection",
        "start": 4.14,
        "duration": 4.459
    },
    {
        "text": "process thank you very much",
        "start": 5.13,
        "duration": 6.24
    },
    {
        "text": "so that's the title of my talk so",
        "start": 8.599,
        "duration": 6.431
    },
    {
        "text": "imagine a world without cancer it's",
        "start": 11.37,
        "duration": 4.739
    },
    {
        "text": "beautiful isn't it",
        "start": 15.03,
        "duration": 4.02
    },
    {
        "text": "no pain no suffering no fear of losing",
        "start": 16.109,
        "duration": 5.821
    },
    {
        "text": "loved ones to cancer well the good news",
        "start": 19.05,
        "duration": 5.88
    },
    {
        "text": "is you are much closer to making this a",
        "start": 21.93,
        "duration": 5.429
    },
    {
        "text": "reality than ever before and I believe",
        "start": 24.93,
        "duration": 5.249
    },
    {
        "text": "that the answer to achieving this isn't",
        "start": 27.359,
        "duration": 5.4
    },
    {
        "text": "cancer immunotherapy how let me show you",
        "start": 30.179,
        "duration": 6.15
    },
    {
        "text": "a short movie here a cancer cell is",
        "start": 32.759,
        "duration": 5.311
    },
    {
        "text": "getting attacked by an immune cell",
        "start": 36.329,
        "duration": 4.5
    },
    {
        "text": "called P cell and this possibility of",
        "start": 38.07,
        "duration": 4.739
    },
    {
        "text": "harnessing our own immune system to",
        "start": 40.829,
        "duration": 4.261
    },
    {
        "text": "target tumors is the future of cancer",
        "start": 42.809,
        "duration": 4.98
    },
    {
        "text": "therapy indeed if you pick up any",
        "start": 45.09,
        "duration": 5.039
    },
    {
        "text": "leading journal or a magazine they have",
        "start": 47.789,
        "duration": 3.901
    },
    {
        "text": "featured cancer immunotherapy as a",
        "start": 50.129,
        "duration": 3.75
    },
    {
        "text": "breakthrough or something that has a",
        "start": 51.69,
        "duration": 5.4
    },
    {
        "text": "potential to cure cancer but there are",
        "start": 53.879,
        "duration": 4.59
    },
    {
        "text": "several challenges that have been",
        "start": 57.09,
        "duration": 3.84
    },
    {
        "text": "identified that need to be overcome in",
        "start": 58.469,
        "duration": 4.89
    },
    {
        "text": "order to I realized the full potential",
        "start": 60.93,
        "duration": 4.439
    },
    {
        "text": "of cancer immunotherapy and my lab",
        "start": 63.359,
        "duration": 3.661
    },
    {
        "text": "currently works on addressing those",
        "start": 65.369,
        "duration": 3.961
    },
    {
        "text": "challenges but before I go into that I",
        "start": 67.02,
        "duration": 4.41
    },
    {
        "text": "would like to share my journey that led",
        "start": 69.33,
        "duration": 5.76
    },
    {
        "text": "to my current work in cancer I'm from a",
        "start": 71.43,
        "duration": 6.06
    },
    {
        "text": "small city in a western state of",
        "start": 75.09,
        "duration": 4.349
    },
    {
        "text": "Maharashtra in India my initial",
        "start": 77.49,
        "duration": 3.809
    },
    {
        "text": "education was in a local language the",
        "start": 79.439,
        "duration": 4.081
    },
    {
        "text": "language you might have seen in the list",
        "start": 81.299,
        "duration": 5.011
    },
    {
        "text": "before in fact the first time I",
        "start": 83.52,
        "duration": 4.47
    },
    {
        "text": "encountered English was during my",
        "start": 86.31,
        "duration": 4.08
    },
    {
        "text": "undergraduate education at instead of",
        "start": 87.99,
        "duration": 4.47
    },
    {
        "text": "chemical technology in Mumbai it was a",
        "start": 90.39,
        "duration": 4.11
    },
    {
        "text": "great learning experience I learned how",
        "start": 92.46,
        "duration": 4.11
    },
    {
        "text": "to synthesize molecules and also scale",
        "start": 94.5,
        "duration": 3.689
    },
    {
        "text": "it up to a full fledged production plan",
        "start": 96.57,
        "duration": 3.24
    },
    {
        "text": "but I was more interested in",
        "start": 98.189,
        "duration": 3.75
    },
    {
        "text": "understanding how this molecules behave",
        "start": 99.81,
        "duration": 4.769
    },
    {
        "text": "in biological systems and that is when I",
        "start": 101.939,
        "duration": 4.981
    },
    {
        "text": "joined University of Cincinnati where I",
        "start": 104.579,
        "duration": 4.171
    },
    {
        "text": "worked on developing black and reasoning",
        "start": 106.92,
        "duration": 4.8
    },
    {
        "text": "platforms I developed there are these",
        "start": 108.75,
        "duration": 4.95
    },
    {
        "text": "black hands that could be used to in",
        "start": 111.72,
        "duration": 5.34
    },
    {
        "text": "address or probe interesting biological",
        "start": 113.7,
        "duration": 6.3
    },
    {
        "text": "questions but during my graduate studies",
        "start": 117.06,
        "duration": 4.65
    },
    {
        "text": "I developed interest in not only",
        "start": 120.0,
        "duration": 3.96
    },
    {
        "text": "designing molecules to probe interesting",
        "start": 121.71,
        "duration": 4.38
    },
    {
        "text": "questions but also can it be used for",
        "start": 123.96,
        "duration": 4.26
    },
    {
        "text": "therapeutic applications so during my",
        "start": 126.09,
        "duration": 4.77
    },
    {
        "text": "postdoctoral studies I I worked on",
        "start": 128.22,
        "duration": 3.86
    },
    {
        "text": "developing nanoscale",
        "start": 130.86,
        "duration": 3.23
    },
    {
        "text": "approaches for cancer limited by",
        "start": 132.08,
        "duration": 3.69
    },
    {
        "text": "applications at Harvard Medical School",
        "start": 134.09,
        "duration": 4.14
    },
    {
        "text": "and Brigham Women's Hospital and last",
        "start": 135.77,
        "duration": 4.59
    },
    {
        "text": "couple of years have been working on",
        "start": 138.23,
        "duration": 4.59
    },
    {
        "text": "developing nanoscale approaches as an",
        "start": 140.36,
        "duration": 4.05
    },
    {
        "text": "independent faculty at Harvard Medical",
        "start": 142.82,
        "duration": 3.81
    },
    {
        "text": "School for therapeutic immune modulation",
        "start": 144.41,
        "duration": 5.16
    },
    {
        "text": "in cancer and from next week I'll be",
        "start": 146.63,
        "duration": 5.64
    },
    {
        "text": "joining initiative masters at how much",
        "start": 149.57,
        "duration": 5.07
    },
    {
        "text": "I'll be working on developing nanoscale",
        "start": 152.27,
        "duration": 4.53
    },
    {
        "text": "platform technologies for Terra",
        "start": 154.64,
        "duration": 4.44
    },
    {
        "text": "predicament modulation in cancer now as",
        "start": 156.8,
        "duration": 4.47
    },
    {
        "text": "I previously explained there are several",
        "start": 159.08,
        "duration": 4.35
    },
    {
        "text": "challenges that need to be overcome in",
        "start": 161.27,
        "duration": 4.8
    },
    {
        "text": "order to fully I didn't in order to",
        "start": 163.43,
        "duration": 4.2
    },
    {
        "text": "fully realize the potential of cancer",
        "start": 166.07,
        "duration": 3.33
    },
    {
        "text": "immunotherapy and one of the biggest",
        "start": 167.63,
        "duration": 3.54
    },
    {
        "text": "challenge is that this immunotherapy",
        "start": 169.4,
        "duration": 3.42
    },
    {
        "text": "drug works in only small patient",
        "start": 171.17,
        "duration": 4.11
    },
    {
        "text": "population for example one of the drug",
        "start": 172.82,
        "duration": 4.68
    },
    {
        "text": "called anti PP do an antibody that",
        "start": 175.28,
        "duration": 5.16
    },
    {
        "text": "activates the t-cells that kills it the",
        "start": 177.5,
        "duration": 4.53
    },
    {
        "text": "cancer cells I have shown to be",
        "start": 180.44,
        "duration": 4.28
    },
    {
        "text": "effective only in 20% of the population",
        "start": 182.03,
        "duration": 5.52
    },
    {
        "text": "now the question is what happens to this",
        "start": 184.72,
        "duration": 4.6
    },
    {
        "text": "80 percent remaining 80 percent of the",
        "start": 187.55,
        "duration": 5.13
    },
    {
        "text": "population and why don't they respond it",
        "start": 189.32,
        "duration": 5.639
    },
    {
        "text": "turns out that tumors dominantly",
        "start": 192.68,
        "duration": 4.35
    },
    {
        "text": "suppress anti-tumor immunity through",
        "start": 194.959,
        "duration": 4.741
    },
    {
        "text": "various mechanisms and that need to be",
        "start": 197.03,
        "duration": 4.98
    },
    {
        "text": "overcome in order to make sure that we",
        "start": 199.7,
        "duration": 4.53
    },
    {
        "text": "get this remaining patients to respond",
        "start": 202.01,
        "duration": 4.53
    },
    {
        "text": "and my lab currently works on exactly",
        "start": 204.23,
        "duration": 4.229
    },
    {
        "text": "addressing those challenges so just to",
        "start": 206.54,
        "duration": 4.32
    },
    {
        "text": "outline we are at trying to address two",
        "start": 208.459,
        "duration": 4.201
    },
    {
        "text": "important questions in cancer",
        "start": 210.86,
        "duration": 4.29
    },
    {
        "text": "immunotherapy how do we overcome tumor",
        "start": 212.66,
        "duration": 4.62
    },
    {
        "text": "in this human separation by developing",
        "start": 215.15,
        "duration": 4.26
    },
    {
        "text": "nanoscale approaches that can not only",
        "start": 217.28,
        "duration": 4.14
    },
    {
        "text": "activate immune dual anti-tumor immunity",
        "start": 219.41,
        "duration": 3.829
    },
    {
        "text": "but can also lead to tumor regression",
        "start": 221.42,
        "duration": 4.7
    },
    {
        "text": "the second question is can be developed",
        "start": 223.239,
        "duration": 5.5
    },
    {
        "text": "imaging platforms that can allow us to",
        "start": 226.12,
        "duration": 4.839
    },
    {
        "text": "in real time monitor if the patient is",
        "start": 228.739,
        "duration": 4.081
    },
    {
        "text": "working or not and that is something",
        "start": 230.959,
        "duration": 5.401
    },
    {
        "text": "that I'd be talking about today now the",
        "start": 232.82,
        "duration": 5.37
    },
    {
        "text": "question comes is why do we need to",
        "start": 236.36,
        "duration": 3.78
    },
    {
        "text": "monitor the response early on as I",
        "start": 238.19,
        "duration": 4.32
    },
    {
        "text": "previously said only limited patient",
        "start": 240.14,
        "duration": 4.08
    },
    {
        "text": "populations respond to this cancer",
        "start": 242.51,
        "duration": 3.54
    },
    {
        "text": "immune therapy applications so if we can",
        "start": 244.22,
        "duration": 3.57
    },
    {
        "text": "identify patients that are not",
        "start": 246.05,
        "duration": 3.81
    },
    {
        "text": "responding early on we can then switch",
        "start": 247.79,
        "duration": 4.759
    },
    {
        "text": "them to a different treatment regimen",
        "start": 249.86,
        "duration": 5.909
    },
    {
        "text": "now developing this platforms for cancer",
        "start": 252.549,
        "duration": 3.791
    },
    {
        "text": "immunotherapy",
        "start": 255.769,
        "duration": 2.551
    },
    {
        "text": "there is a there is one of one big",
        "start": 256.34,
        "duration": 3.329
    },
    {
        "text": "challenge and that's called pseudo",
        "start": 258.32,
        "duration": 3.719
    },
    {
        "text": "progression so what what does that mean",
        "start": 259.669,
        "duration": 3.81
    },
    {
        "text": "that we'll have explained in the next",
        "start": 262.039,
        "duration": 3.361
    },
    {
        "text": "slide so",
        "start": 263.479,
        "duration": 5.251
    },
    {
        "text": "using a conventional chemotherapy drugs",
        "start": 265.4,
        "duration": 5.88
    },
    {
        "text": "if there's a if the patient is",
        "start": 268.73,
        "duration": 4.08
    },
    {
        "text": "responding there will be a decrease in",
        "start": 271.28,
        "duration": 2.97
    },
    {
        "text": "tumor volume which should be considered",
        "start": 272.81,
        "duration": 4.59
    },
    {
        "text": "as the patient is responding to the",
        "start": 274.25,
        "duration": 5.43
    },
    {
        "text": "tumor treatment whereas if the patient",
        "start": 277.4,
        "duration": 3.299
    },
    {
        "text": "is not responding",
        "start": 279.68,
        "duration": 2.67
    },
    {
        "text": "there'll be an increase in tumor volume",
        "start": 280.699,
        "duration": 4.291
    },
    {
        "text": "over time and will be considered as this",
        "start": 282.35,
        "duration": 5.97
    },
    {
        "text": "is progression so it's simple if this is",
        "start": 284.99,
        "duration": 5.489
    },
    {
        "text": "a decrease in tumor volume over time the",
        "start": 288.32,
        "duration": 4.11
    },
    {
        "text": "patient is responding if there if that",
        "start": 290.479,
        "duration": 3.421
    },
    {
        "text": "there is an increase in tumor volume",
        "start": 292.43,
        "duration": 3.6
    },
    {
        "text": "over time the pair of question is not",
        "start": 293.9,
        "duration": 4.47
    },
    {
        "text": "responding whereas in case of cancer",
        "start": 296.03,
        "duration": 6.15
    },
    {
        "text": "immunotherapy if the drug is working the",
        "start": 298.37,
        "duration": 6.15
    },
    {
        "text": "immunotherapy drug activates the immune",
        "start": 302.18,
        "duration": 4.17
    },
    {
        "text": "cells and this activated immune cells",
        "start": 304.52,
        "duration": 3.72
    },
    {
        "text": "then flock to the tumor and because of",
        "start": 306.35,
        "duration": 4.23
    },
    {
        "text": "this heavy infiltration of the immune",
        "start": 308.24,
        "duration": 4.679
    },
    {
        "text": "cells there is a bulking up of the tumor",
        "start": 310.58,
        "duration": 4.77
    },
    {
        "text": "and this bulking up of the tumor can be",
        "start": 312.919,
        "duration": 4.651
    },
    {
        "text": "easily misconstrued as disease",
        "start": 315.35,
        "duration": 4.289
    },
    {
        "text": "progression so currently there are no",
        "start": 317.57,
        "duration": 3.84
    },
    {
        "text": "techniques that can differentiate",
        "start": 319.639,
        "duration": 4.231
    },
    {
        "text": "between this is progression and pseudo",
        "start": 321.41,
        "duration": 5.22
    },
    {
        "text": "progression in fact current clinical",
        "start": 323.87,
        "duration": 4.23
    },
    {
        "text": "guidelines says that if there is an",
        "start": 326.63,
        "duration": 3.9
    },
    {
        "text": "increase in tumor volume after initial",
        "start": 328.1,
        "duration": 4.86
    },
    {
        "text": "treatments you consider this as a pseudo",
        "start": 330.53,
        "duration": 3.99
    },
    {
        "text": "progression and keep giving the",
        "start": 332.96,
        "duration": 4.26
    },
    {
        "text": "treatments to the to the patients till",
        "start": 334.52,
        "duration": 4.8
    },
    {
        "text": "you at a later time point ill you figure",
        "start": 337.22,
        "duration": 4.68
    },
    {
        "text": "out if actually it is progression or if",
        "start": 339.32,
        "duration": 5.43
    },
    {
        "text": "it is the patient is responding so that",
        "start": 341.9,
        "duration": 4.56
    },
    {
        "text": "is something that we want to work on is",
        "start": 344.75,
        "duration": 3.51
    },
    {
        "text": "differentiate between this is",
        "start": 346.46,
        "duration": 3.72
    },
    {
        "text": "progression and pseudo progression the",
        "start": 348.26,
        "duration": 3.99
    },
    {
        "text": "problem is current imaging techniques",
        "start": 350.18,
        "duration": 4.32
    },
    {
        "text": "have limitations for example if you",
        "start": 352.25,
        "duration": 3.84
    },
    {
        "text": "directly just measure the tumor volume",
        "start": 354.5,
        "duration": 4.229
    },
    {
        "text": "it takes much longer time in order to",
        "start": 356.09,
        "duration": 5.16
    },
    {
        "text": "identify if the tumors are responding or",
        "start": 358.729,
        "duration": 5.761
    },
    {
        "text": "not pay CT which is currently a gold",
        "start": 361.25,
        "duration": 4.74
    },
    {
        "text": "standard in monitoring the human",
        "start": 364.49,
        "duration": 3.57
    },
    {
        "text": "response are not really effective in",
        "start": 365.99,
        "duration": 4.32
    },
    {
        "text": "telling you early on if the tumors are",
        "start": 368.06,
        "duration": 4.109
    },
    {
        "text": "responding or not so there are these",
        "start": 370.31,
        "duration": 4.46
    },
    {
        "text": "limitations that can hamper the",
        "start": 372.169,
        "duration": 4.831
    },
    {
        "text": "development of imaging techniques for",
        "start": 374.77,
        "duration": 5.2
    },
    {
        "text": "immunotherapy applications so consider a",
        "start": 377.0,
        "duration": 5.46
    },
    {
        "text": "new paradigm where we develop a",
        "start": 379.97,
        "duration": 4.35
    },
    {
        "text": "technique that can not only deliver a",
        "start": 382.46,
        "duration": 3.959
    },
    {
        "text": "drug specifically to your tumor thereby",
        "start": 384.32,
        "duration": 4.11
    },
    {
        "text": "activating the risk immune response but",
        "start": 386.419,
        "duration": 3.301
    },
    {
        "text": "can actually tell you in real time",
        "start": 388.43,
        "duration": 4.02
    },
    {
        "text": "whether drug is working or not to go one",
        "start": 389.72,
        "duration": 4.74
    },
    {
        "text": "step further if you can actually",
        "start": 392.45,
        "duration": 3.69
    },
    {
        "text": "differentiate between the asian tumor",
        "start": 394.46,
        "duration": 3.63
    },
    {
        "text": "and sensitive to mark that would be",
        "start": 396.14,
        "duration": 2.459
    },
    {
        "text": "really",
        "start": 398.09,
        "duration": 2.43
    },
    {
        "text": "critical for identifying patients that",
        "start": 398.599,
        "duration": 5.43
    },
    {
        "text": "are not responding early on so we are we",
        "start": 400.52,
        "duration": 4.979
    },
    {
        "text": "we have developed this platform",
        "start": 404.029,
        "duration": 3.66
    },
    {
        "text": "technology that can not only allow us to",
        "start": 405.499,
        "duration": 3.87
    },
    {
        "text": "deliver drug but can also test in real",
        "start": 407.689,
        "duration": 3.54
    },
    {
        "text": "time if the drug is working or not",
        "start": 409.369,
        "duration": 4.14
    },
    {
        "text": "we have also sure that you can use it to",
        "start": 411.229,
        "duration": 3.72
    },
    {
        "text": "differentiate between the instant tumor",
        "start": 413.509,
        "duration": 3.75
    },
    {
        "text": "and sensitive tumor so what is this",
        "start": 414.949,
        "duration": 5.071
    },
    {
        "text": "platform technology we have a stimuli",
        "start": 417.259,
        "duration": 4.83
    },
    {
        "text": "responsive polymer construct where we",
        "start": 420.02,
        "duration": 3.75
    },
    {
        "text": "conjugate a drug to the polymer",
        "start": 422.089,
        "duration": 3.84
    },
    {
        "text": "construct and also activatable imaging",
        "start": 423.77,
        "duration": 4.679
    },
    {
        "text": "agent now activity ageing agent is in",
        "start": 425.929,
        "duration": 5.73
    },
    {
        "text": "off condition we optimize the drug and",
        "start": 428.449,
        "duration": 5.61
    },
    {
        "text": "the activity imaging agent ratio in a",
        "start": 431.659,
        "duration": 4.081
    },
    {
        "text": "way that they self-assemble to a",
        "start": 434.059,
        "duration": 4.17
    },
    {
        "text": "nanoparticle the idea is that when this",
        "start": 435.74,
        "duration": 4.349
    },
    {
        "text": "nanoparticle internalized into the tumor",
        "start": 438.229,
        "duration": 3.511
    },
    {
        "text": "if it activates the immune response",
        "start": 440.089,
        "duration": 3.931
    },
    {
        "text": "there will be a physiological changes in",
        "start": 441.74,
        "duration": 4.469
    },
    {
        "text": "the tumor and because those because of",
        "start": 444.02,
        "duration": 3.929
    },
    {
        "text": "those physiological changes it can",
        "start": 446.209,
        "duration": 4.05
    },
    {
        "text": "activate the imaging agent so what it",
        "start": 447.949,
        "duration": 4.2
    },
    {
        "text": "means that if the patient is responding",
        "start": 450.259,
        "duration": 4.921
    },
    {
        "text": "and you know in that and there is an",
        "start": 452.149,
        "duration": 4.681
    },
    {
        "text": "immune response would be able to in",
        "start": 455.18,
        "duration": 5.219
    },
    {
        "text": "real-time know whether there is any drug",
        "start": 456.83,
        "duration": 5.85
    },
    {
        "text": "working or not whereas if there is no",
        "start": 460.399,
        "duration": 3.42
    },
    {
        "text": "immune response there'll be no",
        "start": 462.68,
        "duration": 3.12
    },
    {
        "text": "activation of the imaging agent and will",
        "start": 463.819,
        "duration": 5.16
    },
    {
        "text": "not see any any response and we can say",
        "start": 465.8,
        "duration": 5.729
    },
    {
        "text": "that the patient is not responding now",
        "start": 468.979,
        "duration": 4.65
    },
    {
        "text": "we wanted to first validate this",
        "start": 471.529,
        "duration": 3.99
    },
    {
        "text": "platform for a very established",
        "start": 473.629,
        "duration": 4.32
    },
    {
        "text": "chemotherapy drug so we conjugated a",
        "start": 475.519,
        "duration": 4.411
    },
    {
        "text": "chemotherapy drug here and a",
        "start": 477.949,
        "duration": 4.08
    },
    {
        "text": "near-infrared dye based activity will",
        "start": 479.93,
        "duration": 4.139
    },
    {
        "text": "imaging agent B can you we can use this",
        "start": 482.029,
        "duration": 4.59
    },
    {
        "text": "for monitoring the response in Enlai",
        "start": 484.069,
        "duration": 6.84
    },
    {
        "text": "mice and when we injected this into",
        "start": 486.619,
        "duration": 6.03
    },
    {
        "text": "three different doses and then image it",
        "start": 490.909,
        "duration": 3.9
    },
    {
        "text": "at different time points the idea was",
        "start": 492.649,
        "duration": 4.56
    },
    {
        "text": "that then we will be able to see if the",
        "start": 494.809,
        "duration": 4.26
    },
    {
        "text": "patient service per patients are",
        "start": 497.209,
        "duration": 4.29
    },
    {
        "text": "responding or not in real-time we first",
        "start": 499.069,
        "duration": 4.111
    },
    {
        "text": "started with control nano thermal sticks",
        "start": 501.499,
        "duration": 4.17
    },
    {
        "text": "which had only the activity wedging",
        "start": 503.18,
        "duration": 5.549
    },
    {
        "text": "agent and did not have any drug the idea",
        "start": 505.669,
        "duration": 4.71
    },
    {
        "text": "was to see if you get nonspecific",
        "start": 508.729,
        "duration": 4.261
    },
    {
        "text": "activation of the imaging agent and when",
        "start": 510.379,
        "duration": 4.741
    },
    {
        "text": "we saw that we did not get using the",
        "start": 512.99,
        "duration": 3.69
    },
    {
        "text": "control Natha no sticks we do not get",
        "start": 515.12,
        "duration": 4.349
    },
    {
        "text": "any nonspecific activation of the of the",
        "start": 516.68,
        "duration": 5.279
    },
    {
        "text": "image agent which means that this probe",
        "start": 519.469,
        "duration": 5.761
    },
    {
        "text": "is very specific to to them and respond",
        "start": 521.959,
        "duration": 6.0
    },
    {
        "text": "to the drug activation whereas when we",
        "start": 525.23,
        "duration": 4.859
    },
    {
        "text": "used reporter nano thermal sticks we see",
        "start": 527.959,
        "duration": 5.011
    },
    {
        "text": "that we get much higher activation of",
        "start": 530.089,
        "duration": 5.401
    },
    {
        "text": "the fluorescence signal at a different",
        "start": 532.97,
        "duration": 4.23
    },
    {
        "text": "time points after the injections as",
        "start": 535.49,
        "duration": 3.48
    },
    {
        "text": "compared to control natural noxious and",
        "start": 537.2,
        "duration": 3.36
    },
    {
        "text": "will be quantified we see that we get",
        "start": 538.97,
        "duration": 4.02
    },
    {
        "text": "much higher tumour to normal tissue",
        "start": 540.56,
        "duration": 5.4
    },
    {
        "text": "ratio when we I used and report on after",
        "start": 542.99,
        "duration": 4.35
    },
    {
        "text": "Gnostics as compared to control",
        "start": 545.96,
        "duration": 3.75
    },
    {
        "text": "nanotechnology which means that we can",
        "start": 547.34,
        "duration": 4.47
    },
    {
        "text": "not only deliver a drug to the tumor we",
        "start": 549.71,
        "duration": 4.46
    },
    {
        "text": "can also monitor the response early on",
        "start": 551.81,
        "duration": 4.95
    },
    {
        "text": "this was very exciting next we wanted to",
        "start": 554.17,
        "duration": 4.24
    },
    {
        "text": "see was can we actually use it to",
        "start": 556.76,
        "duration": 4.11
    },
    {
        "text": "differentiate between resistant tumor",
        "start": 558.41,
        "duration": 4.92
    },
    {
        "text": "and sensitive tumor to do that we design",
        "start": 560.87,
        "duration": 4.98
    },
    {
        "text": "an animal model where we had sensory",
        "start": 563.33,
        "duration": 4.71
    },
    {
        "text": "tumor on the right side and resistant",
        "start": 565.85,
        "duration": 3.99
    },
    {
        "text": "tumor on the left side and then again we",
        "start": 568.04,
        "duration": 3.18
    },
    {
        "text": "did different doses and image at",
        "start": 569.84,
        "duration": 3.12
    },
    {
        "text": "different time points and as you can see",
        "start": 571.22,
        "duration": 3.45
    },
    {
        "text": "are using report on death gnostics we",
        "start": 572.96,
        "duration": 3.96
    },
    {
        "text": "could indeed differentiate between sense",
        "start": 574.67,
        "duration": 3.75
    },
    {
        "text": "of humor and resistant tumor where we",
        "start": 576.92,
        "duration": 4.32
    },
    {
        "text": "saw much higher signal in the and in the",
        "start": 578.42,
        "duration": 4.23
    },
    {
        "text": "sensory tumor as compared to the",
        "start": 581.24,
        "duration": 2.79
    },
    {
        "text": "resistant humour and I can be getting",
        "start": 582.65,
        "duration": 3.18
    },
    {
        "text": "much better tumor to normal tissue ratio",
        "start": 584.03,
        "duration": 4.29
    },
    {
        "text": "in sensitive tumor this was really",
        "start": 585.83,
        "duration": 4.17
    },
    {
        "text": "exciting because this is the first time",
        "start": 588.32,
        "duration": 3.93
    },
    {
        "text": "we can show that you can not only",
        "start": 590.0,
        "duration": 4.35
    },
    {
        "text": "monitor in real-time where the drug is",
        "start": 592.25,
        "duration": 3.84
    },
    {
        "text": "working or not but now we can also",
        "start": 594.35,
        "duration": 4.05
    },
    {
        "text": "differentiate between sensitive tumor",
        "start": 596.09,
        "duration": 5.1
    },
    {
        "text": "and resistant tumor in real-time the",
        "start": 598.4,
        "duration": 4.44
    },
    {
        "text": "next question was now can we use this",
        "start": 601.19,
        "duration": 4.68
    },
    {
        "text": "for monitoring immunotherapy response so",
        "start": 602.84,
        "duration": 6.15
    },
    {
        "text": "to do that we design a new report on",
        "start": 605.87,
        "duration": 4.83
    },
    {
        "text": "ortho gnostics will be conjugated and",
        "start": 608.99,
        "duration": 3.54
    },
    {
        "text": "TPD one antibody which is an",
        "start": 610.7,
        "duration": 4.89
    },
    {
        "text": "immunotherapy drug and then NIR base",
        "start": 612.53,
        "duration": 6.12
    },
    {
        "text": "active damaging agent we also use IgG as",
        "start": 615.59,
        "duration": 5.58
    },
    {
        "text": "a control to show that we get much",
        "start": 618.65,
        "duration": 4.68
    },
    {
        "text": "better response using immunotherapy drug",
        "start": 621.17,
        "duration": 4.71
    },
    {
        "text": "as compared to control and we can see",
        "start": 623.33,
        "duration": 5.04
    },
    {
        "text": "here and that we can get response as",
        "start": 625.88,
        "duration": 5.52
    },
    {
        "text": "early as 3 to 5 days when we use report",
        "start": 628.37,
        "duration": 5.34
    },
    {
        "text": "on optimistic as compared to control",
        "start": 631.4,
        "duration": 3.96
    },
    {
        "text": "reported at ninth or Gnostics now I",
        "start": 633.71,
        "duration": 2.72
    },
    {
        "text": "would like to point out here that",
        "start": 635.36,
        "duration": 3.63
    },
    {
        "text": "immunotherapy response takes longer time",
        "start": 636.43,
        "duration": 5.56
    },
    {
        "text": "so the activation is actually delayed as",
        "start": 638.99,
        "duration": 4.95
    },
    {
        "text": "compared to chemotherapy drugs where we",
        "start": 641.99,
        "duration": 3.75
    },
    {
        "text": "could in keep in case of chemotherapy",
        "start": 643.94,
        "duration": 3.84
    },
    {
        "text": "drug we could detect as or less 12 hours",
        "start": 645.74,
        "duration": 4.11
    },
    {
        "text": "whereas in case of emergency drop you",
        "start": 647.78,
        "duration": 5.34
    },
    {
        "text": "took around 3 to 5 days in getting the",
        "start": 649.85,
        "duration": 5.73
    },
    {
        "text": "signal but when we compare it with a",
        "start": 653.12,
        "duration": 4.92
    },
    {
        "text": "current gold standard which is PET CT",
        "start": 655.58,
        "duration": 5.25
    },
    {
        "text": "we could not detect any difference even",
        "start": 658.04,
        "duration": 5.73
    },
    {
        "text": "early as 3 days or even 7 days so",
        "start": 660.83,
        "duration": 5.04
    },
    {
        "text": "basically this imaging techniques of not",
        "start": 663.77,
        "duration": 2.64
    },
    {
        "text": "used",
        "start": 665.87,
        "duration": 3.57
    },
    {
        "text": "in identifying if the tumors are",
        "start": 666.41,
        "duration": 6.36
    },
    {
        "text": "responding or not early on so this is",
        "start": 669.44,
        "duration": 5.34
    },
    {
        "text": "the first time we have shown that using",
        "start": 672.77,
        "duration": 4.65
    },
    {
        "text": "an activatable imaging system we can",
        "start": 674.78,
        "duration": 6.21
    },
    {
        "text": "measure if the therapy if you are if the",
        "start": 677.42,
        "duration": 5.31
    },
    {
        "text": "pill if the tumors are responding to the",
        "start": 680.99,
        "duration": 4.98
    },
    {
        "text": "therapy or not the next question is how",
        "start": 682.73,
        "duration": 5.64
    },
    {
        "text": "do we adapt this technology for clinical",
        "start": 685.97,
        "duration": 4.74
    },
    {
        "text": "setting and that is exactly what we are",
        "start": 688.37,
        "duration": 3.93
    },
    {
        "text": "currently working on we are developing",
        "start": 690.71,
        "duration": 4.53
    },
    {
        "text": "platforms that can be adopted for",
        "start": 692.3,
        "duration": 4.86
    },
    {
        "text": "clinical applications and that can be",
        "start": 695.24,
        "duration": 4.5
    },
    {
        "text": "used for clinical clinically usable",
        "start": 697.16,
        "duration": 4.47
    },
    {
        "text": "imaging systems as well as biodegradable",
        "start": 699.74,
        "duration": 4.59
    },
    {
        "text": "and biocompatible components and that",
        "start": 701.63,
        "duration": 5.19
    },
    {
        "text": "can be used for easy clinical",
        "start": 704.33,
        "duration": 5.28
    },
    {
        "text": "translation so just to summarize my talk",
        "start": 706.82,
        "duration": 5.34
    },
    {
        "text": "we are working on addressing two",
        "start": 709.61,
        "duration": 3.87
    },
    {
        "text": "important questions in cancer",
        "start": 712.16,
        "duration": 4.08
    },
    {
        "text": "immunotherapy can be identified or",
        "start": 713.48,
        "duration": 5.1
    },
    {
        "text": "developed nanoscale approaches that can",
        "start": 716.24,
        "duration": 4.23
    },
    {
        "text": "overcome humour induce immune",
        "start": 718.58,
        "duration": 3.83
    },
    {
        "text": "suppression and then also can be",
        "start": 720.47,
        "duration": 4.26
    },
    {
        "text": "developed imaging platforms that can",
        "start": 722.41,
        "duration": 4.24
    },
    {
        "text": "allow us to monitor the methyl-p",
        "start": 724.73,
        "duration": 5.28
    },
    {
        "text": "response early on so with that I would",
        "start": 726.65,
        "duration": 5.76
    },
    {
        "text": "like to thank all the team members who",
        "start": 730.01,
        "duration": 5.67
    },
    {
        "text": "have been incredible in in in generating",
        "start": 732.41,
        "duration": 5.55
    },
    {
        "text": "some of the data as well as the",
        "start": 735.68,
        "duration": 3.54
    },
    {
        "text": "collaborators who supported me",
        "start": 737.96,
        "duration": 4.44
    },
    {
        "text": "throughout this work and my funding",
        "start": 739.22,
        "duration": 4.5
    },
    {
        "text": "agencies who have been kind enough to",
        "start": 742.4,
        "duration": 3.51
    },
    {
        "text": "believe in our work and I'd like to",
        "start": 743.72,
        "duration": 4.5
    },
    {
        "text": "thank you all for coming and again CNN",
        "start": 745.91,
        "duration": 5.06
    },
    {
        "text": "for this great honor",
        "start": 748.22,
        "duration": 2.75
    },
    {
        "text": "you",
        "start": 753.5,
        "duration": 2.06
    }
]